Fulgent Genetics Valuation
Is FLGT * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of FLGT * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FLGT * (MX$445) is trading above our estimate of fair value (MX$139.42)
Significantly Below Fair Value: FLGT * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FLGT *?
Other financial metrics that can be useful for relative valuation.
| What is FLGT *'s n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | n/a |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does FLGT *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.9x | ||
MEDICA B Médica Sur. de | 0.8x | 5.5% | Mex$3.1b |
OPK OPKO Health | 1.4x | 6.4% | US$1.0b |
4694 BML | 0.8x | 2.5% | JP¥109.0b |
HLS Healius | 0.7x | -4.5% | AU$1.1b |
FLGT * Fulgent Genetics | 2.3x | 9.8% | Mex$687.1m |
Price-To-Sales vs Peers: FLGT * is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (0.9x).
Price to Earnings Ratio vs Industry
How does FLGT *'s PE Ratio compare vs other companies in the South American Healthcare Industry?
Price-To-Sales vs Industry: FLGT * is expensive based on its Price-To-Sales Ratio (2.3x) compared to the South American Healthcare industry average (0.8x).
Price to Sales Ratio vs Fair Ratio
What is FLGT *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate FLGT *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$445.00 | Mex$537.12 +20.7% | 6.1% | Mex$582.42 | Mex$504.76 | n/a | 3 |
| Nov ’25 | Mex$409.00 | Mex$537.12 +31.3% | 6.1% | Mex$582.42 | Mex$504.76 | n/a | 3 |
| Oct ’25 | Mex$400.00 | Mex$537.12 +34.3% | 6.1% | Mex$582.42 | Mex$504.76 | n/a | 3 |
| Sep ’25 | Mex$435.00 | Mex$537.12 +23.5% | 6.1% | Mex$582.42 | Mex$504.76 | n/a | 3 |
| Aug ’25 | n/a | Mex$452.55 0% | 8.8% | Mex$509.12 | Mex$424.26 | n/a | 3 |
| Jul ’25 | n/a | Mex$452.55 0% | 8.8% | Mex$509.12 | Mex$424.26 | n/a | 3 |
| Jun ’25 | n/a | Mex$452.55 0% | 8.8% | Mex$509.12 | Mex$424.26 | n/a | 3 |
| May ’25 | n/a | Mex$450.21 0% | 8.8% | Mex$506.49 | Mex$422.08 | n/a | 3 |
| Apr ’25 | n/a | Mex$450.21 0% | 8.8% | Mex$506.49 | Mex$422.08 | n/a | 3 |
| Mar ’25 | Mex$402.50 | Mex$471.66 +17.2% | 7.4% | Mex$511.44 | Mex$426.20 | n/a | 3 |
| Feb ’25 | n/a | Mex$570.80 0% | 10.1% | Mex$611.57 | Mex$489.26 | n/a | 3 |
| Jan ’25 | n/a | Mex$570.80 0% | 10.1% | Mex$611.57 | Mex$489.26 | n/a | 3 |
| Dec ’24 | n/a | Mex$550.12 0% | 11.1% | Mex$611.24 | Mex$488.99 | n/a | 2 |
| Nov ’24 | Mex$437.00 | Mex$653.50 +49.5% | 23.3% | Mex$805.69 | Mex$501.32 | Mex$409.00 | 2 |
| Oct ’24 | n/a | Mex$702.17 0% | 9.8% | Mex$770.67 | Mex$633.67 | Mex$400.00 | 2 |
| Sep ’24 | Mex$571.55 | Mex$752.29 +31.6% | 12.2% | Mex$854.88 | Mex$632.61 | Mex$435.00 | 3 |
| Aug ’24 | n/a | Mex$753.65 0% | 8.9% | Mex$801.12 | Mex$658.70 | n/a | 3 |
| Jul ’24 | n/a | Mex$753.65 0% | 8.9% | Mex$801.12 | Mex$658.70 | n/a | 3 |
| Jun ’24 | n/a | Mex$753.65 0% | 8.9% | Mex$801.12 | Mex$658.70 | n/a | 3 |
| May ’24 | n/a | Mex$791.18 0% | 11.3% | Mex$854.47 | Mex$664.59 | n/a | 3 |
| Apr ’24 | n/a | Mex$791.18 0% | 11.3% | Mex$854.47 | Mex$664.59 | n/a | 3 |
| Mar ’24 | n/a | Mex$784.46 0% | 5.4% | Mex$814.63 | Mex$724.12 | Mex$402.50 | 3 |
| Feb ’24 | n/a | Mex$883.41 0% | 9.1% | Mex$981.57 | Mex$785.25 | n/a | 3 |
| Jan ’24 | n/a | Mex$883.41 0% | 9.1% | Mex$981.57 | Mex$785.25 | n/a | 3 |
| Dec ’23 | n/a | Mex$1,036.91 0% | 15.9% | Mex$1,263.73 | Mex$874.89 | n/a | 3 |
| Nov ’23 | n/a | Mex$1,344.40 0% | 3.7% | Mex$1,394.20 | Mex$1,294.61 | Mex$437.00 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.